checkAd

     113  0 Kommentare Kite Receives U.S. FDA Approval of Viral Vector Manufacturing Facility in Southern California to Produce Commercial Product - Seite 3

    Kite, the Kite logo, and GILEAD are trademarks of Gilead Sciences, Inc. or its related companies.

    For more information on Kite, please visit the company’s website at www.kitepharma.com. Follow Kite on social media on Facebook, Twitter (@KitePharma), LinkedIn and YouTube.

    Lesen Sie auch


    The Gilead Sciences Stock at the time of publication of the news with a raise of +1,00 % to 63,58USD on Tradegate stock exchange (03. Oktober 2022, 14:59 Uhr).

    Diskutieren Sie über die enthaltenen Werte


    Business Wire (engl.)
    0 Follower
    Autor folgen
    RSS-Feed abonnieren

    Weitere Artikel des Autors

    Seite 3 von 3

    Verfasst von Business Wire (engl.)
    1 im Artikel enthaltener WertIm Artikel enthaltene Werte
    Kite Receives U.S. FDA Approval of Viral Vector Manufacturing Facility in Southern California to Produce Commercial Product - Seite 3 Kite, a Gilead Company (Nasdaq: GILD), today announced the U.S. Food and Drug Administration (FDA) has approved the company's retroviral vector (RVV) manufacturing facility in Oceanside, California, for commercial production. Viral vectors are key …

    Artikel zu den Werten

    Auch bei Lesern beliebt

    Schreibe Deinen Kommentar

    Disclaimer